Article
Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
British journal of haematology - 1 Jul 2020
Zhou Ya-Lan, Wu Li-Xin, Peter Gale Robert, Wang Zi-Long, Li Jin-Lan, Jiang Hao, Jiang Qian, Jiang Bin, Cao Shan-Bo, Lou Feng, Sun Ying, Wang Cheng-Cheng, Liu Yan-Rong, Wang Yu, Chang Ying-Jun, Xu Lan-Ping, Zhang Xiao-Hui, Liu Kai-Yan, Ruan Guo-Rui, Huang Xiao-Jun
Abstract excerpt
About 25% of patients with newly diagnosed acute myeloid leukaemia (AML) have normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). The prognosis and best therapy for these patients is controversial. We evaluated 158 newly diagnosed adults with this genotype who achieved histological complete remission within two cycles of induction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
